Nanoparticles

Details for Australian Patent Application No. 2006281232 (hide)

Owner Nanoco Technologies Limited

Inventors O'Brien, Paul; Daniels, Steven; Pickett, Nigel

Agent Griffith Hack

Pub. Number AU-B-2006281232

PCT Pub. Number WO2007/020416

Priority 0516598.0 12.08.05 GB

Filing date 14 August 2006

Wipo publication date 22 February 2007

Acceptance publication date 21 April 2011

International Classifications

C30B 7/00 (2006.01) Single-crystal growth from liquids

B82B 3/00 (2006.01) Manufacture or treatment of nano-structures

C01G 9/08 (2006.01) Compounds of zinc

C09K 11/02 (2006.01) Luminescent, e.g. electroluminescent, chemiluminescent, materials - Use of particular materials as binders, particle coatings or suspension media therefor

C30B 29/60 (2006.01) Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape

H01L 31/0296 (2006.01) Semiconductor devices sensitive to infra-red radiation, light, electromagnetic radiation of shorter wavelength, or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation

Event Publications

28 February 2008 PCT application entered the National Phase

  PCT publication WO2007/020416 Priority application(s): WO2007/020416

21 April 2011 Application Accepted

  Published as AU-B-2006281232

18 August 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006281237-Crystalline and amorphous sodium atorvastatin

2006281229-Crystalline and amorphous sodium atorvastatin